Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid for myeloma bone disease (renal function–stratified)
ChiCTR2200063438Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of denosumab in multiple myeloma (MM) (3 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Time to first skeletal-related event (SRE). Planned start Oct 2022; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200063438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063438.